Gonasi

Gonasi is a prescription medication that contains the hormone human chorionic gonadotropin (hCG) as its active ingredient. It is supplied as an injectable solution for intramuscular or subcutaneous use, with the specific strength defined by the prescribing information. Marketed in the European Union, Gonasi belongs to the gonadotropin hormone class and is intended for use under the supervision of a qualified healthcare professional.

Gonasi is employed in several reproductive‑health settings where stimulation of luteinizing hormone receptors is required.

- Induction of ovulation in women with anovulatory infertility. - Luteal phase support during assisted reproductive technology cycles. - Treatment of cryptorchidism in male infants. - Stimulation of testosterone production in men with hypogonadism. - Adjunct therapy in certain cases of delayed puberty.

Side effects of Gonasi vary in frequency and severity.

Common: - Injection site pain or bruising. - Headache. - Nausea or mild abdominal discomfort. - Breast tenderness or swelling. - Mild fluid retention.

Serious: - Ovarian hyperstimulation syndrome (OHSS). - Allergic reactions such as rash, itching, or anaphylaxis. - Thromboembolic events. - Severe abdominal pain indicating ovarian torsion. - Rapid weight gain due to fluid overload.

Before initiating Gonasi therapy, several safety considerations should be reviewed.

- Confirm pregnancy status; avoid use in confirmed pregnancy unless specifically indicated. - Assess for ovarian cysts or enlarged ovaries prior to dosing. - Monitor patients with a history of thromboembolic disease closely. - Use caution in individuals with uncontrolled hypertension or cardiovascular disease. - Evaluate for hypersensitivity to hCG or any formulation components. - Adjust dosing in patients with severe renal or hepatic impairment as directed by a physician.

Gonasi may interact with other medications or substances that affect hormonal balance or coagulation.

Avoid: - Concurrent use of high‑dose estrogen therapy, which may increase the risk of ovarian hyperstimulation. - Anticoagulant agents without close monitoring, due to potential additive thrombotic risk.

Use with caution: - Gonadotropin‑releasing hormone (GnRH) agonists or antagonists. - Steroid hormones such as testosterone or anabolic steroids. - Medications that alter fluid balance, e.g., diuretics. - Drugs that affect liver enzymes (CYP450) which could modify hCG metabolism.